An observational study in Coronary Artery Disease, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by German Heart Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.
Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 84th largest by planned enrollment of the 117 observational ones that give a count, is one of 7 that started in 2026, is one of 117 observational ones, reaches primary completion later than 41 of the 70 other live ones, and was the 346th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 2 more countries
Ages 18–80
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Emory University · Sites in Germany, United States, Serbia
Ages 18+
B. Braun Melsungen AG · Sites in Germany, Switzerland
Ages 18+
Philipps University Marburg · Sites in Germany
Ages 30+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
365 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 39 · Phase 4 47
First in 1999; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is below the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 265 across the 248 interventional studies, 550 across the 117 observational. Of the 237 that completed or were terminated, 56 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 365 have an industry lead sponsor. The 10 most frequent:
German Heart Institute is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
German Heart Institute has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Coronary Artery Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04196712University Hospital, EssenEssen Coronary Artery Disease Registry | 2026-12-30 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05540223Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System | 2027-02 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 365 studies in Coronary Artery Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease (CAD) is the clinically relevant manifestation of atherosclerosis affecting the coronary arteries. CAD is associated with an increased risk of morbidity and mortality and typically presents as angina pectoris or dyspnea. Non-invasive imaging techniques are recommended for the diagnosis of CAD. Of particular importance is stress perfusion cardiac magnetic resonance imaging (CMR), which is distinguished from other recommended diagnostic modalities by its high diagnostic accuracy and the absence of exposure of patients and healthcare professionals to ionizing radiation. Consequently, stress perfusion CMR has been assigned a Class I recommendation in international cardiology guidelines.
The aim of this study is to demonstrate the feasibility of transferring the clinical routine workflow for the diagnostic evaluation of patients with suspected coronary artery disease (CAD) from stationary, specialized centers to mobile MRI units.
This will be demonstrated by comparing two groups. In one group, stress CMR examinations will be performed using mobile MRI units, while in the other group, examinations will be conducted in stationary imaging facilities. Participants will be randomly assigned to one of the two groups.
The diagnostic examinations conducted as part of this study will be performed using stress perfusion cardiac magnetic resonance imaging (CMR) with the pharmacologically active agent regadenoson and the contrast agent gadobutrol. A total of 250 patients with a clinical suspicion of hemodynamically significant coronary artery disease (CAD) will undergo stress perfusion CMR using the pharmacologically active vasodilator regadenoson and the contrast agent gadobutrol. Examinations will be performed in either mobile or stationary MRI units. By introducing stress CMR as a mobile diagnostic service, state-of-the-art, highly accurate diagnostic imaging can also be made available in rural areas. This will enable timely diagnostic examinations close to patients' homes, both for patients with abnormal findings and suspected coronary artery disease and for further diagnostic evaluation of patients with already established CAD. Mobile stress CMR diagnostics will provide the treating specialist with additional information to support clinical decision-making regarding the timely initiation of targeted treatment in the cardiac catheterization laboratory, potentially having a positive impact on subsequent treatment and prognosis.
The study aims to achieve the following objectives:
To demonstrate the feasibility of easily performing stress perfusion CMR in a mobile setting using a short, patient- and user-friendly MRI protocol that is identical to the protocol established in clinical routine practice and recommended by professional societies.
Our hypothesis is that there are no differences in the performance of stress CMR examinations in a mobile setting compared with a stationary setting. The primary endpoints are the proportion of successfully completed and evaluable stress CMR examinations with at least adequate image quality.
The criteria were revised on the registry on Nov 12, 2026. See what changed
The study population consists of adults with a clinical indication for invasive cardiac diagnostic evaluation due to suspected or known coronary artery disease (CAD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults based one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with suspected coronary artery disease will undergo a clinical indicated stress CMR examination in a mobile MRI unit using stress agent Regadenoson and contrast agent gadobutrol. Stress cardiac examination will be performed In accordance with the protocol established in clinical routine practice and consistent with the MRI examinations performed in the stationary setting group.
Diagnostic Test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease
Adult patients with suspected coronary artery disease will undergo a clinical indicated stress CMR examination in a stationary MRI unit using stress agent Regadenoson and contrast agent gadobutrol. Stress cardiac examination will be performed In accordance with the protocol established in clinical routine practice.
Diagnostic Test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease
Performing stress cardiac MRI in mobile MRI units vs. stationary MRI units for clinical diagnosis in adult patients with suspected coronary artery disease
Proportion of unsuccessful or non-evaluable stress CMR examinations
The primary endpoint is the proportion of unsuccessful or non-evaluable stress CMR examinations (e.g., due to adverse events or insufficient image quality) under an identical examination protocol. In the stationary setting, this proportion is approximately 3%. It is assumed that the proportion will also be 3% in the mobile setting, with mobile stress CMR being considered non-inferior provided that the proportion of unsuccessful or non-evaluable stress CMR examinations does not exceed 10%. Based on these assumptions, a non-inferiority test with a one-sided significance level of 2.5% will have 80% power if 94 patients are enrolled in each study arm.
Time frame: at baseline
Plan to share: Undecided
Started Nov 2026 (actual). Primary completion is estimated for Jun 2027, 7 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 7 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jun 2025 → Nov 2026, primary completion Dec 2025 → Jun 2027 and completion Dec 2025 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
German Heart Institute